| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/CLPT.1984.118 |
| P698 | PubMed publication ID | 6734034 |
| P2093 | author name string | D J Birkett | |
| J Säwe | |||
| M Eichelbaum | |||
| L Bertilsson | |||
| F Sjöqvist | |||
| R Dahlqvist | |||
| P433 | issue | 6 | |
| P304 | page(s) | 815-821 | |
| P577 | publication date | 1984-06-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism | |
| P478 | volume | 35 |
| Q53768812 | An examination of a possible pharmacokinetic interaction between nifedipine and antipyrine. |
| Q34448073 | Antipyrine clearance and metabolism in patients with psoriasis |
| Q71497746 | Antipyrine, theophylline, and hexobarbital as in vivo P450 probe drugs |
| Q70058771 | Carbamazepine metabolism in man. Induction and pharmacogenetic aspects |
| Q69373690 | Clinical significance of the sparteine/debrisoquine oxidation polymorphism |
| Q51050930 | Determination of theophylline clearance in South African children. |
| Q39283612 | Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects models |
| Q69665183 | Felodipine reduces the absorption of theophylline in man |
| Q44947499 | Genetically determined polymorphisms in drug oxidation |
| Q34626564 | Polymorphism of theophylline metabolism in man. |
| Q34418061 | Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach |
| Q68411894 | Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide |
| Q41922262 | Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine |
| Q70490332 | The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women |
| Q36851934 | Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions |
Search more.